Oesophageal Cancer: PET Does Not Improve Treatment
Cancer patients are often given chemo- or radiotherapy, with the aim of shrinking the tumour before it is surgically removed. PET is an imaging technique that makes a tumour in the oesophagus visible without the need for the patient to undergo an invasive examination. Especially during treatment cycles in which the tumour is supposed to shrink, it makes sense to check the tumour's response to the treatment. To date, however, no benefit for patients has ensued, according to Milly Schröer-Günther, MD, Institute for Quality and Efficiency in Healthcare (IQWiG), Cologne, Germany, and co-authors.
Dr. Schröer-Günther and colleagues conducted a systematic review of all available data to assess the benefit for patients of using PET to assess the response of oesophageal cancer to chemo- or radiotherapy. They searched the Medline, Embase, and Cochrane Library databases for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing PET with conventional techniques such as endosonography and computed tomography (CT). They did not find any RCTs or CCTs that addressed the question of the patient-relevant benefit of PET.
According to the researchers, the studies they have analysed have often investigated only a small number of patients or that their results are biased. Nevertheless, they say, PET carried out early on in treatment does have the potential to identify patients who will not respond to that treatment, and these patients could then be spared continuing treatment with its associated side effects. To reach this point, however, will require randomised controlled trials.
Source: Deutsches Ärzteblatt International
Image credit: Wikimedia Commons
Published on : Tue, 8 Sep 2015
About the Affirm® breast biopsy guidance system Our passion to offer innovative interventional tools that advance breast health fueled the development of the Affirm breast biopsy guidance system. This simple add-on to any Hologic 3D Mammography™-capable...
Newly redesigned Precision Flow Packettes™ allow pinpoint application to a transducer head or skin surface while eliminating the potential for gel cross-contamination. Available for Aquasonic® 100 and hypoallergenic Aquasonic CLEAR®. FEATURES...
Redefining the Vision of Cardiovascular The LISENDO 880 is Hitachi’s premium 2D/4D diagnostic ultrasound solution for cardiologists in any clinical setting. The LISENDO 880 platform is redefining the vision for cardiac ultrasound by providing exceptional...